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Abstract
Background: Parkinson’s disease (PD) is a complex disorder caused by genetic, environmental and age-related
factors, and it is more prevalent in men. We aimed to identify differentially expressed genes in peripheral blood
leukocytes (PBLs) that might be involved in PD pathogenesis. Transcriptomes of 30 female PD-patients and 29 age-
and sex-matched controls were profiled using GeneChip Human Exon 1.0 ST Arrays. Samples were from unrelated
Ashkenazi individuals, non-carriers of LRRK2 G2019S or GBA founder mutations.
Results: Differential expression was detected in 115 genes (206 exons), with over-representation of immune
response annotations. Thirty genes were related to B cell functions, including the uniquely B cell-expressed IGHM
and IGHD, the B cell surface molecules CD19, CD22 and CD79A, and the B cell gene regulator, PAX5. Quantitative-
RT-PCR confirmation of these 6 genes in 79 individuals demonstrated decreased expression, mainly in women
patients, independent of PD-pharmacotherapy status.
Conclusions: Our results suggest that the down regulation of genes related to B cell activity reflect the
involvement of these cells in PD in Ashkenazi individuals and represents a molecular aspect of gender-specificity in
PD.
Background
Parkinson’s disease (PD) is a complex disorder involving
multiple affected genes and multiple environmental risk
factors [1]. It is the second most common neurodegen-
erative disorder, affecting about 1.8% of the population
over the age of 65 years [2]. Since the identification of
mutations in the a-synuclein gene [3], 16 chromosomal
loci, and mutations in 9 genes have been associated with
familial and sporadic PD (reviewed by [4]). Abnormal-
ities in multiple cellular pathways including the ubiqui-
tin-proteasome, mitochondrial and apoptotic pathways
and impaired protection from oxidative stress were sug-
gested to be involved in the accumulation of synuclein
and the selective loss of dopaminergic and other neu-
rons (reviewed by [5]). Transcriptional profiling by
microarray methodology of the substantia nigra (SN)
from PD-patients [6-8], as well as from peripheral blood
leukocytes (PBL) from PD-patients [9,10] further
demonstrated expression changes in genes belonging to
these pathways. The identification of similar expression
changes in SN and PBL encouraged our use of PBL as a
surrogate tissue to search for novel genes and cellular
pathways that might be involved in PD pathogenesis.
Genetic analysis of isolated populations derived from
relatively few founders offers a powerful route for the
identification of genetic risk factors [11]. The Ashkenazi
Jewish population has preserved its homogeneous
genetic makeup, and has been valuable for the identifi-
cation of genes associated with increased risk for many
common complex diseases, relevant to the world popu-
lation-at-large [12,13]. In our previous studies, muta-
tions in the LRRK2 and GBA genes were detected in a
surprisingly high proportion (more than a third) of the
Ashkenazi PD-patients tested [14,15], allowing the sub-
classification of these patients based on their LRRK2 or
GBA carrier status.
Gender differences in PD are well characterized, with
PD prevalence being about 1.5 times lower in women
than in men in Western populations [16,17]. Phenotypic
changes between men and women have also been
described, for example, age at PD onset is ~3 years later
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developing cognitive impairment [18].
To increase the possibility of identifying PD-related
expression changes in patients’ PBL, we studied the rela-
tively genetically homogenous population of Ashkenazi
patients and controls. To further increase the homoge-
neity of the studied population in the initial step of the
microarray expression profiling, we included only female
patients and controls that do not carry the LRRK2 or
GBA Ashkenazi founder mutations. The microarray
methodology was designed to capture the expression
intensity of each exon individually, allowing the identifi-
cation of differentially expressed genes in PD-patients
compared to healthy controls.
Results
Quality control and batch effects removal
Principal component analysis (PCA) revealed two meth-
odological factors that affected the expression levels, the
Affymetrix whole-transcript target labeling kit batches
(2 batches, Additional file 1, Figure S1, A) and the two
researchers who extracted the RNAs (Additional file 1,
Figure S1, B). Successful elimination of the batch effects
and data homogeneity were demonstrated in PCA done
following the batch-removed ANOVA function (Partek
®
Genomics Suite Version 6.4, Additional file 1, Figures
S1, C and D).
Expression changes detected in PBL from Parkinson’s
disease patients
Of the 232,448 core exon-level probesets data in the
Human Exon 1.0 array, 195,437 had mean signal value
of 3.0 or more in all samples, 227 of them were signifi-
cantly changed between PD-patients and controls (3-
way ANOVA, P <0 . 0 1a n df o l d - c h a n g e( F C )>1 . 5o r<
-1.5). Filtering out probesets with known SNPs resulted
in 206 probesets that were incorporated into 115 genes
(Figure 1A and 1B; Additional file 2, Table S1). 160 pro-
besets (75 genes) were down-regulated and 46 probesets
(40 genes) were up-regulated in PD-patients’ PBL com-
pared to controls. Alternative-splicing, including possi-
ble exon skipping and alternative 3’ or 5’ sites, was
detected in 76 out of the 115 differentially expressed
genes using the Partek’s gene view tool (Additional file
2 ,T a b l eS 1 ) .I n t e r e s t i n g l y ,1 3o ft h e1 1 5d i f f e r e n t i a l l y
expressed genes have previously been reported to be
c h a n g e di nt h es u b s t a n t i an i g r a( S N )f r o mP D - p a t i e n t s
[6,8,19-22]. In five of these genes (ADCY2, CCDC92,
CELSR1, HECTD2 and KIF1B) the direction of expres-
sion change in patients’ PBL were as those reported in
dopaminergic neurons captured by laser microdissection
from patients’ SN [6,19]. Twelve of the differentially
expressed genes (10.4%) likely belong to PD-related
pathways based on their GO annotations (DAVID
functional analysis tools, http://david.abcc.ncifcrf.gov/):
the ubiquitin-proteasome pathway (FBXL13, HECTD2
and PSMC5), mitochondrial dysfunction (ACSM5,
KIF1B,a n dMMAA); increased oxidative stress (GPX3)
and apoptosis and cell death (CKAP2, DDIT4, IFNG,
NEB and TRAJ17).
Genes associated with immune response, specifically with
B cell-related functions, are differentially expressed in PD-
patients
Significantly enriched GO-annotations were identified
when comparing their representation in the 115 signifi-
cantly changed genes to their representation on the
Human Exon 1.0 ST array (21,980 genes, Figure 2 and
Additional file 3, Table S2). Genes involved in the
immune response were most significantly enriched (17
genes, P = 2.69*10
-8), including genes involved in the
innate and humeral immune responses (5 genes each, P
= 2.29*10
-4 and, P = 3.85*10
-3 respectively). Additional
enriched functional annotations were genes with signal
transduction activity (29 genes [P = 6.17*10
-5], 21 of
them with receptor activity [P =2 . 6 * 1 0
-3], mostly
immuno-receptors) and voltage-gated ion channels (5
genes [P =1 . 1 3 * 1 0
-2], 3 of them calcium channels [P =
1.11*10
-3]). Of note, the same significantly enriched
annotations were also identified when we compared the
representations of the GO-annotations between the 115
differentially expressed genes and the list of genes
expressed in our PBL samples (17,441 genes, data not
shown).
Significantly over-represented KEGG pathways were
also identified (Table 1), and the most significantly
enriched pathway was “B cell receptor signaling” (8/115
genes, P = 2.21*10
-8, 19.1 times higher than expected;
Table 2A). Notably, such enrichment was not detected
in other lymphocyte signaling pathways, such as T cell
Figure 1 Significant expression changes in peripheral blood
leukocytes of Parkinson’s disease patients compared to
controls.( A) Schematic representation of the statistical analysis and
the filters applied on the Affymetrix GeneChip Human Exon 1.0 ST
Array exon-level expression data. The numbers of exon-level
probesets remained after each filtering step are indicated in circles.
(B) PCA mapping of patients and control samples according to the
expression levels of the 206 significantly changed exon probesets.
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toxicity, but was unique to the B cell pathway.
We further generated a combined list of genes
included in all B cell-relateda n n o t a t i o n s ,u s i n gD A V I D
functional analysis tools (342 genes listed in Additional
file 4, Table S3 from GO, KEGG, Biocarta, BBID,
UniProt Tissue and UniProt Keywords databases; http://
david.abcc.ncifcrf.gov/[23,24]). A significant enrichment
of genes that carry B cell-related annotations was identi-
fied among the 115 changed genes (19/115, Tables 2A
and 2B) compared to all genes in the core-level Exon
1.0 array (342/21,980, c
2 test, c
2 = 159.43, P < 0.0001),
and to all genes expressed in our PBL samples (272/
17,441, P < 0.0001, c
2 test, c
2 = 156.9, P < 0.0001).
Furthermore, 11 additional genes that are associated
with B cells were also detected via a manual search of
the following databases: GeneCard, UniProt Tissue Spe-
cificity, UniProt Function and PubMed (Table 2C). In
total, a high proportion (26%) of the significantly chan-
g e dg e n e s( 3 0 / 1 1 5 ,T a b l e2 )w a sr e l a t e dt oBc e l lf u n c -
tions. Although some of these genes may carry
additional roles, their common significantly enriched
functions related to B cell biology. Notably, among these
genes were IGHM and IGHD that are uniquely
expressed in B cells, and the CD19 gene, which is fre-
quently used as a marker for B cell identification.
Positive correlations between the differentially expressed
genes
The Pearson Correlation test performed between the
115 significantly changed transcripts in all 59 patient
and control samples identified 54 highly significant cor-
relations (threshold: r > 0.8 and P <1 0
-14, Additional
file 5, Table S4). Two gene-networks were generated
based on these correlations (Cytoscape, Figure 3), sug-
gesting a co-regulation of the gene expression. The large
gene-network included multiple correlations between 19
genes; all were down-regulated in patients’ PBL, most of
them (16/19) were immune response genes (Additional
file 4, Table S3). In particular, 13 of these 19 highly cor-
related genes are B cell-related (Table 2, bold circle in
Figure 3). The second gene-network (Figure 3) linked 3
genes, CD8B and KLRG1 that are expressed in T cells,
and MCOLN2 that was suggested to play a role in B cell
lysosomal function [25].
Validation
Of the 115 significantly changed genes, 10 genes were
chosen for validation, representing both up- and down-
regulated genes as well as different GO-annotations,
including immune and defense responses (CD22, CD19,
CD79A, IGHD and IGHM), regulation of cell prolifera-
tion and differentiation (EREG), regulation of transcrip-
tion (PAX5), voltage-gated ion channel (KCNH8)a n d
cell-cell adhesion (PCDH9). The SNCA gene, whose
expression levels were not changed between patients
and controls, was used as negative control. Validation of
the expression results was done using RNA samples
from 9 PD-patients and 6 controls that were also hybri-
d i z e dt ot h eH u m a nE x o n1 . 0S Ta r r a y .H i g h l y
Figure 2 Functional annotation analysis. Significantly over-
represented GO annotations were detected among the 115
changed genes (206 exon probesets). Only GO annotations with at
least 3 genes and P < 0.01 (Fisher exact probability) are presented
here. The complete data of enriched GO annotations with P < 0.05
and a threshold of 2 genes are available in Additional file 3, Table
S2. For each annotation, the dark bar represents the number of
observed genes among the differentially expressed genes, and the
grey bar represents the number of expected genes among the
core-level Human Exon 1.0 ST Array.
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between the expression levels resulting from both meth-
ods in all tested genes [ranged between r = 0.864 (P <
0.0005) and r = 0.666 (P = 0.007); Additional file 6,
Table S5].
Are the expression levels of B cell-related genes affected
by disease state, disease duration, medication or gender?
We expanded the number of RNA samples analyzed by
Real-Time PCR (total of 79) to include an additional 64
samples from males and females patients and controls
who were not tested on the microarrays. Six B cell-
related genes were analyzed: CD22, CD19 and CD79A
that encode B cell surface molecules, IGHD and IGHM
that encode B cell specific immunoglobulins, and PAX5
that encodes a regulator of B cell genes. In order to
define whether disease state (PD), rather than PD phar-
macological therapy, affected the expression levels, we
included 20 samples from patients who were not treated
at the time of enrollment ("naïve"-PD group, with dis-
ease duration of 1.65 ± 1.42 years). Two additional
groups of medically treated patients were included in
this extended analysis: 18 patients with short disease
duration (PD-SDD, less than 2 years between onset of
motor symptoms to enrollment), and 20 with long dis-
ease duration (PD-LDD, more than 5 years between
onset of motor symptoms to enrollment). Importantly,
all four experimental groups of patients and controls
included men and women in ~1:1 ratio (total of 39 men
and 40 women).
First, a 2-way ANOVA, with experimental group and
gender as independent variables, revealed the significant
effects of both parameters on the expression levels of all
tested B cell-related genes (Figure 4AI-FI). Additionally,
significant interactions between gender and experimen-
tal group were detected for CD19, CD22, IGHD and
IGHM ( F i g u r e4 A I ,B I ,D Ia n d4 E I ) .N e x t ,m e na n d
women were analyzed separately. In men, none of the
genes tested, except CD79A (Figure 4CIII), were signifi-
cantly changed between the four experimental groups.
In contrast, in women, all tested B cell-related genes
were differentially expressed between the control group
and the different PD-groups (1-way ANOVA, followed
by Tukey post hoc, Figure 4AII-FII). Compared to con-
trols, the expression of the 6 B cell-related genes was
down-regulated in all female patient groups, naïve and
treated (Figure 4AII-FII). Further decreased expression
levels were noted for all tested genes, except for CD19,
in the patient group with long disease duration (Figure
4B-F). Finally, the expression levels of the negative con-
trol gene, SNCA, and the two internal control genes,
TBP and GUSB, were not changed between the four
experimental groups, nor were they changed between
men and women (Figures 4GI-III and 4HI-III). Taken
together, these results demonstrate that the expression
levels of these B cell-related genes are affected by the
disease status, regardless of medication, mainly in
women PD-patients.
Studying the B cell related genes expression in other PD
patient populations and in other neurological diseases
The expression levels of four of the B cell related genes
(IGHD, IGHM, CD19 and CD22)w e r ea l s oe x a m i n e di n
10 non-Ashkenazi female PD patients and 11 non-Ash-
kenazi female controls. No changes in the expression
levels of these genes were detected between PD-patients
and controls (Additional file 7, Figure S2). Notably, the
expression levels in non-Ashkenazi PD women (patients
and controls) were similar to the expression levels in
the Ashkenazi control women. These results might sug-
gest that the observed changes in B cell related genes
are specific to the Ashkenazi PD women population.
To examine the expression of the B cell related genes
in other independent PD cohort and in patients with
other neurological diseases we re-analyzed the pre-
viously published data by Scherzer at al. ([9]; GSE6613).
This dataset compares PD patients to healthy controls
and to other neurological disease controls. Based on our
criteria for detecting differentially expressed genes (P <
0.01 and FC > 1.5 or < -1.5), no significant changes in
Table 1 Enriched KEGG pathways among the 115 changed transcripts
KEGG pathway Genes in pathway Enrichment
B cell receptor signaling pathway BLNK, CD19, CD22, CD72, CD79A, CD79B, CR2, RASGRP3 O = 8;E = 0.419;R = 19.111;P = 2.21e
-8
Hematopoietic cell lineage CD19, CD22, CD8B, CR2, FCER2, IL1R2 O = 6;E = 0.546;R = 10.995;P = 2.60e
-5
Type II diabetes mellitus CACNA1C, CACNA1D, IRS2 O = 3;E = 0.284;R = 10.560;P = 3.45e
-3
Calcium signaling pathway ADCY2, CACNA1C, CACNA1D, GNAL, P2RX5 O = 5;E = 1.114;R = 4.489;P = 5.78e
-3
MAPK signaling pathway CACNA1C, CACNA1D, CACNB4, IL1R2, RASGRF1, RASGRP3 O = 6;E = 1.779;R = 3.373;P = 9.64e
-3
ABC transporters - General ABCA13, ABCB4 O = 2;E = 0.254;R = 7.868;P = 2.92e
-2
GnRH signaling pathway ADCY2, CACNA1C, CACNA1D O = 3;E = 0.650;R = 4.613;P = 2.93e
-2
Cell adhesion molecules (CAMs) CD22, CD40, CD8B O = 3;E = 0.807;R = 3.716;P = 4.95e
-2
O, Observed number of genes carrying the annotation among the 115 differentially expressed genes; E, expected number of genes that carry this annotation
among all core-level genes on the array; R, ratio between observed and expected; P, P-value of the enrichment, calculated using Fisher exact test.
Kedmi et al. Molecular Neurodegeneration 2011, 6:66
http://www.molecularneurodegeneration.com/content/6/1/66
Page 4 of 12Table 2 B cell-related genes with significantly changed expression in PBL of PD-patients
Symbol GenBank
Accession No
Gene Name B cells involvement
A. Genes involved in B cell receptor signaling pathway
BLNK NM_013314 B-cell linker B cell receptor signaling pathway (a); B cell activation (b), (g); B cell differentiation (b)
CD19 NM_001770 CD19 antigen B cell receptor signaling pathway (a); Expressed in B-cell (f), (g)
CD22 NM_001771 CD22 antigen B cell receptor signaling pathway (a); Expressed in B-cell (f), (g)
CD72 NM_001782 CD72 antigen B cell receptor signaling pathway (a); Expressed in B-cell (g)
CD79A NM_001783 CD79A antigen (immunoglobulin-
associated alpha)
B cell receptor signaling pathway (a),(b); B cell differentiation (b); B cell proliferation
(b); B cell receptor complex (c)
CD79B NM_000626 CD79B antigen (immunoglobulin-
associated beta)
B cell receptor signaling pathway (a),(b); B cell receptor complex (c)
CR2 NM_001006658 complement component (3d/
epstein barr virus) receptor 2
B cell receptor signaling pathway (a); B Lymphocyte Cell Surface Molecules (d)
RASGRP3 NM_170672 ras guanyl releasing protein 3
(calcium and dag-regulated)
B cell receptor signaling pathway (a)
B. Genes involved in other B cell-related annotations
BANK1 NM_017935 B-cell scaffold protein with
ankyrin repeats 1
B cell activation (b)
CD40 NM_001250 CD40 antigen (tnf receptor
superfamily member 5)
Positive regulation of B cell activation (b); Positive regulation of B cell proliferation
(b); B cell mediated immunity (b)
EBF1 NM_024007 early b-cell factor B Cell Development (e)
FCER2 NM_002002 FC fragment of ige, low affinity ii,
receptor for (cd23a)
Expressed in B-cell (f), (g)
IFNG NM_000619 interferon, gamma Positive regulation of B cell activation (b); B cell mediated immunity (b)
IGHD BC021276 immunoglobulin heavy constant
delta
Expressed in primary B-Cells (f)
IGHM BC001872 immunoglobulin heavy constant
mu
Positive regulation of B cell proliferation B cell receptor signaling pathway (b); B cell
receptor complex (c); B Cell Development; B cell activation (e); Expressed in primary
B-Cells (f)
IL1R2 NM_004633 interleukin 1 receptor, type ii Expressed in B-cell (f)
MSC NM_005098 musculin (activated b-cell factor-
1)
Expressed in B-cell (f)
SPIB NM_003121 spi-b transcription factor (spi-1/
pu.1 related)
Expressed in B-cell (f)
TCL1A NM_021966 T-cell leukemia/lymphoma 1a Expressed in B-cell (f)
C. Additional B cell-related genes
CD180 NM_005582 CD180 antigen Expressed mainly on mature B cells (h); May be involved in the life/death decision of
B-cells (j)
CRISP3 NM_006061 cysteine-rich secretory protein 3 Specifically expressed in pre-B cell [50] (i)
FAM129C NM_173544 B-cell novel protein 1 Specifically expressed in B-lymphocytes (k)
FCRL1 NM_052938 FC receptor-like 1 May serve as an activating coreceptor on B cells [51] (i)
FCRL2 NM_030764 FC receptor-like 2 Expression is limited to the mature B-cell lines (h); May have an regulatory role in
normal and neoplastic B cell development (j)
FCRLA NM_032738 FC receptor-like and mucin-like 1 Specifically expressed in B-cells(k)
NFE2L3 NM_004289 nuclear factor (erythroid-derived
2)-like 3
Highly expressed in B-cell (h)
MCOLN2 NM_153259 mucolipin 2 Might play a role in B cell lysosomal function [25] (i)
NT5E NM_002526 5’-nucleotidase, ecto (CD73) Mediates B cell adhesion [52] (i)
PAX5 NM_016734 paired box gene 5 (b-cell lineage
specific activator)
Key regulator of the B-cell-restricted expression of the CD23a isoforms [53] (i)
TBK1 NM_013254 tank-binding kinase 1 TBK1-mediated signaling in haematopoietic cells was critical for the induction of
antigen-specific B and CD4(+) T cells [54] (i)
Involvement in B cells was determined based on: (a) KEGG pathway; (b) GO Biological Process; (c) GO Cellular Component; (d) Biocarta; (e) BBID; (f) UniProt Tissue
database; (g) UniProt Keywords database; (h) UniProt Tissue Specificity; (i) GENERIF_SUMMARY (PubMed); (j) UniProt Function; (k) GeneCards.
Kedmi et al. Molecular Neurodegeneration 2011, 6:66
http://www.molecularneurodegeneration.com/content/6/1/66
Page 5 of 12the expression of the B cell related genes were observed
between any of the three experimental groups, in the
whole cohort or when genders were analyzed separately
(with the exception of IL1R2, which was up-regulated in
males PD patients and was also one of the only up-regu-
lated B cell related genes in our data). These results
might suggest that the changes we observed in the
expression of B cell related genes are not common to
other neurological diseases. However, since we could
not confirm the changes also in the PD-patients it is
possible that other factors might influenced these
results, including demographic properties such as ethni-
city and age of the female patients and controls, as well
as technical aspects, such as the array used and the nor-
malization method in the dataset of Scherzer et al.. For
example, in the original article the authors used the
MAS5 algorithm to normalize the array data, while in
our re-analysis we utilized the GCRMA algorithm. As a
result, out of the 24 probesets defined by Scehrzer at al.
as differentially expressed (Supplementalry Table 3 [9]),
only 8 probesets showed P < 0.01 when analyzing the
data with GCRMA. Taken together, these results might
suggest that the B cell related changes are specific to
Ashkenazi Jewish PD female patients, however, the
results could also be referred to other causes.
Discussion
While transcriptional events in brain tissues from
deceased PD patients have shed light on disease patho-
genesis, recent studies have demonstrated the potential
of PBL as a surrogate tissue in PD research. Mammalian
lymphocytes are capable of synthesizing dopamine (DA)
and other catecholamines, as well as DA receptors and
transporters (DAT) [26,27]. Furthermore, when PBL
from PD-patients were compared to controls, differences
in DA signaling, including reduced DA content,
impaired DAT immunoreactivity [28] and higher levels
of dopamine D1-like and D2-like receptors, were
observed [29]. The hypothesis that PBL can echo some
of the changes occurring in the substantia nigra of PD-
patients is also supported by our results. Changes in
expression levels, in the same direction (up- or down-
regulation), of the ADCY2, CCDC92, CELSR1, HECTD2
and KIF1B genes, were demonstrated both here, in
patients’ PBL, and previously, in the substantia nigra of
PD-patients [6,19]. In addition, genes involved in PD-
related pathways, such as the ubiquitin-proteasome and
apoptosis, and mitochondrial function were differentially
expressed in patients’ PBL both in our study and in
recent reports [9,10]. These results suggest that PBL
from PD-patients serve as an important, easily accessible
tool, that might help in the study of mechanisms under-
lying Parkinson’s disease pathogenesis. Our data also
demonstrated that the selection of a relatively homoge-
neous group of RNA samples from Ashkenazi women
that do not carry either GBA or LRRK2 founder muta-
tions [14,15] increased the ability to detect novel expres-
sion changes in PD patients’ PBL.
The involvement of the immune system, and particu-
larly T cells, in PD has been recognized (reviewed by
[30]). Our expression analysis of PBL from PD-patients
demonstrated that the most prominent group of differ-
entially expressed genes were those involved in immune
system processes. Notably, a significantly decreased
expression of innate and humeral immune response
genes was detected, mainly of genes related to B cell
functions. The down-regulation of dozens of genes
encoding the CD surface molecules, the B cell specific
immunoglobulins IGHM and IGHD, and regulators of B
cell differentiation and activation, suggest a decrease in
the B cell population among women with PD. Such a
decrease in the number and percentage of peripheral
CD19
+ B cells was previously demonstrated in PD-
patients [31]. Indeed, decreased mRNA levels of CD19
w e r ec o n f i r m e di no u rs t u d yb yb o t hm i c r o a r r a ya n d
quantitative real-time PCR analyses. Changes in periph-
eral B and T lymphocytes were also described in other
neurodegenerative disorders, such as Alzheimer’s disease
[32] and amyotrophic lateral sclerosis [33]. Our findings
suggest that B cells might in fact be an additional tissue
involved in PD, which has been recently appreciated as
multi-systemic, beyond the central nervous system,
involving the enteric and autonomic nervous systems as
well as the eye (reviewed by [34] and [35]).
The detection of expression changes in tissues taken
from patients under pharmacotherapy raises the
Figure 3 B cell-related genes in the network of differentially
expressed genes. The Pearson Correlation test between the
expression levels of the 115 differentially changed genes generated
two gene networks. Highly significant correlations with a threshold
of r > 0.8 and P <1 0
-14 are presented here. B cell-related genes are
in bold circles. Complete correlation data are available in Additional
file 5, Table S4.
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therapy, or both. Therefore, the quantitative expression
confirmation analysis included both treated and
untreated (naïve) patients. Our data demonstrated that
the reduced expression levels of B cell-related genes did
not result from anti-parkinsonian medications, but were
related to the presence of PD. This is in agreement with
the decreased number and percentage of CD19
+ B cells
observed in both treated and untreated PD-patients [31].
While our initial microarray expression study tested
only women, we greatly expanded the number of sam-
ples for the confirmation analysis, testing six B cell-
related genes in male and female PD-patients and
controls. Interestingly, the expression levels of all six
genes were significantly under-expressed only in women
patients compared to women controls, whereas in men,
the expression levels were similarly lower in both
patients and controls. Such a gender-dependent differ-
ential expression of B cell-related genes is reminiscent
of the variations detected in the levels of different sub-
sets of lymphocyte populations between healthy men
and women [36,37], specifically, the higher count of
CD19
+ B cells in healthy women compared to men [38].
Additionally, since our analysis of Ashkenazi PD women
samples demonstrated an expression changes in B cell
related genes both in the initial stage and in the
Figure 4 Confirmation of the differential expression of B cell-related genes. Quantitative Real-Time RT-PCR analyses were performed to
confirm the expression changes in CD19, CD22, CD79A, IGHD, IGHM and PAX5 genes (A-F). SNCA gene expression was used as a negative control
(G). Each transcript’s expression level was normalized to the geometric mean of GUSB and TBP expression levels (H). Graphs in column I (AI-HI,
Two-way ANOVA, followed by Tukey post hoc) represent the combined analysis of men and women (79 samples). Each analysis included a
group of sex- and age-matched healthy controls, and three groups of patients: PD-patients that did not receive anti-Parkinson medications at
time of enrollment (naïve-PD), PD-patients with short disease duration (PD-SDD) and PD-patients with long disease duration (PD-LDD). Each of
these four groups included both women and men in a 1:1 ratio. Graphs in columns II and III (AII-HII and AIII-HIII, One-way ANOVA, followed by
Tukey post hoc) represent the separate analysis of women (40 samples) or men (39 samples), respectively. For all gene analyses, bold numbers in
AI-AIII represent the number of individuals tested. Bars represent mean ± SEM. Significant P-values are indicated between the tested groups as
follows: black solid lines represent P < 0.0005, black dashed lines represent P < 0.005 and grey solid lines represent P < 0.05. Statistical
significances were detected (Two-way ANOVA) for both gender and group parameters (#) and for gender and group parameters, as well as the
interaction between them (*).
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Page 7 of 12confirmation study, and given that we could not detect
the same changes in expression patterns in non-Ashke-
nazi PD women (in Jewish women with PD from East-
ern and North-African origin, as well as in Scherzer et
al. [9] cohort), it is possible that these changes might be
specific to Ashkenazi PD women.
Gender-associated phenotypes are well recognized in
PD, particularly the greater prevalence and the younger
age of motor symptom onset in men [17]. Specific dif-
ferences were also detected in peripheral blood, where
serum uric acid levels have been inversely correlated
with disease duration and daily levodopa dosage in
male, but not female PD patients [39]. Recently, gender-
dependent gene expression changes were demonstrated
in the SN of PD-patients, with only a small overlap of
the differentially expressed genes between males and
females [40]. The expression changes detected in B cell-
related genes in our study are yet another example of
molecular variations between men and women with PD.
It will be important to explore the relationship between
the down regulation of B cell-related genes and the
development of PD: Are women with down regulation
of B cell-related genes more prone to develop PD, with
a higher expression of B cell-related genes possibly car-
rying a protective effect? or is it the disease process
itself that decreases the expression of B cell-related
genes in women?
Conclusions
The results presented here demonstrated down-regu-
lated expression of large number of B cell related genes,
including genes that are specifically expressed in B cells
and genes encoding B cell surface molecules. Moreover,
we showed that their expression decreased specifically in
women PD-patients. Our results provide compelling evi-
dence for the involvement of B cells in PD even before
the initiation of anti-Parkinsonian drugs. Further studies
will be needed to elucidate the possible roles of the B
cell down-regulation in PD pathogenesis.
Methods
Patients and controls
All PD-patients and controls tested here were included
in our previous studies [14,15,41], and the diagnostic
criteria, modes of recruitment and genotyping of LRRK2
and GBA mutations were described therein. In the first
step of our study, the microarray analysis, we included
RNA samples from female patients and controls who
were not carriers of either the LRRK2 G2019 or GBA
mutations. A random selection of 30 patients (age at
enrollment, i.e. age at blood sampling 65.7 ± 10.3, range
47-84; age at motor symptoms onset 56 ± 11.58, range
26-84) was done using SPSS software Version 16 (SPSS
Inc., Chicago, IL) from a pool of 86 non-carrier female
patients. The 29 controls were randomly selected to
match the mean, SD and range of the age at enrollment
of the patients, from a group of 91 healthy females (age
at enrollment of 65.48 ± 8.89, range 48-82). For the sec-
ond step of the study, the quantitative RT-PCR (q-RT-
PCR) analysis, we tested 79 RNA samples from males
and females (1:1.03 ratio), PD-patients and controls (58
and 21, respectively). Twenty patients were naïve,
untreated, and 38 were under PD pharmacotherapy.
None were carriers of either the LRRK2 G2019S or GBA
mutations. Fifteen of the 59 samples that were analyzed
by the microarrays in the first step were randomly
selected for validation by q-RT-PCR. In total, 123 RNA
samples were included in these studies (84 females and
39 males). Table 3 summarizes the age and gender of
patients and controls that were used for the q-RT-PCR
analysis. All study samples were from individuals of un-
related Ashkenazi-Jewish ancestry. q-RT-PCR was also
performed using 10 non-Ashkenazi Jewish female PD
patients (age at enrollment of 61.7 ± 8.4) and 11 age-
and ethnicity-matched female controls. Each group
included females from North Africa and Eastern (Iraq,
Iran, Syria) origin. All patients and controls signed an
informed consent and the study was approved by the
Institutional and National Supreme Helsinki Commit-
tees for Genetic Studies.
RNA isolation, target labeling and hybridization
PBL were obtained from 2.5 mL of peripheral blood that
was lyzed within 2 h from blood taking (buffer EL, QIA-
GEN, Germantown, MD). The PBL pellets were imme-
diately frozen and kept at -80°C. Total RNA was
extracted using QIAamp RNA blood Mini Kit in the
presence of DNase (QIAGEN). RNA quality and quan-
tity were measured using NanoDrop spectrophotometer
ND-1000 (NanoDrop Technologies, Wilmington, DE).
Only RNAs that passed the quality control cutoffs of
260/280 ratio of 1.8 and 260/230 ratio of 1.6 were used.
Table 3 Age at enrollment (AAE) and age at onset (AAO)
of the patients’ and controls’ samples used for the q-RT-
PCR assays
GROUP Sex No AAE AAO
Control F 11 61.45 ± 9.10
Control M 10 64.30 ± 8.07
Naive-PD F 10 62.30 ± 12.82 60.50 ± 12.79
Naive-PD M 10 64.50 ± 9.38 62.90 ± 10.08
PD-LDD F 10 65.70 ± 7.82 51.80 ± 10.79
PD-LDD M 10 67.10 ± 10.58 57.50 ± 12.83
PD-SDD F 9 63.00 ± 8.14 62.11 ± 8.37
PD-SDD M 9 64.89 ± 8.65 64.44 ± 8.85
None of the groups showed significant difference in AAE.
No, Number of samples used.
Kedmi et al. Molecular Neurodegeneration 2011, 6:66
http://www.molecularneurodegeneration.com/content/6/1/66
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of total RNA was done according to the manufacturer’s
instructions (GeneChip WT cDNA Synthesis and
Amplification and GeneChip WT Terminal Labeling
Kits, Affymetrix Inc., Santa Clara, CA). The labeled tar-
gets were hybridized to the Affymetrix GeneChip
Human Exon 1.0 ST Arrays. Hybridized arrays were
washed and stained on a GeneChip Fluidics Station 450
and scanned on a GCS3000 Scanner (Affymetrix). Tar-
get labeling, hybridization and scanning were done in
batches of 8 samples, each containing an equal number
of samples from all experimental groups. Microarray
experiments were designed to comply with minimum
information about a microarray experiment (MIAME)
guidelines [42].
Statistical and bioinformatic analyses
Normalization, filtering and statistical analyses were
done using Partek
® Genomics Suite Version 6.4 (Partek
Inc., St. Louis, MO). Background adjustment, normaliza-
tion, and probe-level summarization of the microarray
data were done using the robust multichip average
( R M A )a l g o r i t h m[ 4 3 ]a n ds u m m a r i z e ds i g n a l sw e r e
log2 transformed. Gene-level summarization was done
by calculating the mean signal for each gene, based on
the meta-probeset file provided by Affymetrix. To elimi-
nate the batch effects (scan date and personnel), the
ANOVA-batch-removal tool implanted in Partek was
applied. The first filtering step was done to include only
t h ec o r e - l e v e ld a t ao ft h eH u m a nE x o n1 . 0S Ta r r a ya s
defined by Affymentrix, which includes 21,980 gene and
232,448 exon probesets, consisting of RefSeq and full-
length GenBank mRNAs. To avoid analysis of non-
expressed genes, only exons with signal values of ≥ 3.0
were selected for further analysis. To detect transcrip-
tional changes, 3-way ANOVA was conducted on the
exon-level data, with the disease status and the two
batch-removed effects as the ANOVA factors. To elimi-
nate false-positive results due to probes that site on
SNPs [44], differentially expressed exon-level probesets
that contained SNPs in more than 50% of their probes
were identified using the SNPinProbe1.0 database [45]
and removed. P-values for the ANOVA model were cal-
culated using log-transformed data. Expression fold
changes were calculated by least squares (LS) mean.
Since Partek’s alternative-splicing ANOVA algorithm is
affected by exon-to-exon differences, Partek’sg e n ev i e w
tool was used to determine alternatively-spliced genes.
Pearson correlation test was used to examine possible
correlations between expression levels of the differen-
tially expressed transcripts, which were employed for
expression-based network (Expression correlation plug-
in at Cytoscape software 2.6.1 [46]). To determine func-
tional significance among the changed transcripts, over-
represented gene ontology (GO) and KEGG pathways
were identified, compared to their representation on the
H u m a nE x o n1 . 0S Ta r r a y ,u s i n gt h eo n l i n es o f t w a r e
WebGestalt (http://bioinfo.vanderbilt.edu/webgestalt/
[47]).
Quantitative RT-PCR analysis
cDNA was synthesized from 0.5 μgt o t a lR N Au s i n g
High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA) in the presence of
an RNase inhibitor. The expression levels of the follow-
ing genes were validated: CD19 (Hs01047409_g1), CD22
(Hs00233533_m1), CD79A (Hs00998120_g1), EREG
(Hs00914313_m1), KCNH8 (Hs00976951_m1), IGHD
(Hs00378878_m1), IGHM (Hs00378435_m1), PAX5
(Hs01045956_m1) and PCDH9 (Hs01009199_m1). The
expression of SNCA (Hs01103386_m1) was used here as
negative control, since its expression levels were not
changed between the studied groups in the Affymetrix
E x o n1 . 0a r r a ye x p e r i m e n t( d a t an o ts h o w n ) .T h e
expression levels of all tested genes were normalized
relative to the expression levels of the GUSB
(Hs99999908_m1) and TBP (Hs99999910_m1) genes.
These reference genes were selected based on their
microarray expression out of several candidate reference
genes using NormFinder algorithm, which allows the
selection of genes with the least expression changes
between the different samples and the experimental
groups ([48], data not shown). Quantification was done
using TaqMan MGB probe and TaqMan Universal PCR
Master Mix with 10 ng of cDNA on the StepOne Plus
Real-Time PCR system (Applied Biosystems). Reactions
were performed for 2 min at 50°C, 10 min at 95°C, and
then 45 cycles of 15 s at 95°C and 1 min at 60°C. The
expression levels were determined using the comparative
threshold cycle (CT) quantification method [49]. The
geometric mean of CT values of the internal control
genes, GUSB and TBP, was subtracted from CT values
of each target genes (ΔCT) and signal values are
expressed as 2
(-ΔCT). Pearson correlation test was
applied to examine the correlation between results
obtained from the Exon 1.0 ST Array and the Real-
Time PCR. The expanded confirmation analysis (in 79
s a m p l e sf r o mm e na n dw o m e n )i n c l u d e dt h ef o l l o w i n g
genes: CD19, CD22, CD79A, IGHD, IGHM, PAX5 and
SNCA. Their expression signal values were compared
between the study groups, and 2-way ANOVA with gen-
der and group as the two independent variables, fol-
lowed by 1-way ANOVA statistics were applied.
Analyzing published blood expression profile data of
Parkinson’s and other neurological diseases
To detect whether the expression changes in B cell
related genes seen in our PD patients can be also
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Page 9 of 12detected in other neurological diseases’ patients and in
other PD cohort, we re-analyzed the published data of
Scherzer et al. ([9]; GSE6613). This dataset includes 50
PD patients, 22 healthy controls and 33 controls with
other neurological diseases. The CEL files were down-
loaded to Partek
® Genomics Suite Version 6.5. Back-
ground adjustment and normalization of the microarray
data were done using the GCRMA algorithm. One sam-
ple of healthy control (GSM155358) was detected as an
outlier by PCA, and was removed from further analyses.
Since the gender of the subjects was not provided, we
used the expression of XIST to distinguish between
males and females. According to the XIST expression,
the cohort included 41 females (12 PD patients, 11
healthy controls and 18 other neurological diseases con-
trols) and 63 males (38 PD patients, 11 healthy controls
and 15 other neurological diseases controls). ANOVAs
were done to detect significant changes between PD
patients, healthy controls and controls with other neuro-
logical diseases among: all subjects, only females and
only males.
Additional material
Additional file 1: Supplemental Figure 1: PCA mapping based on
global gene expression. PCA mapping of all RNA samples based on the
expression levels of all exon probesets demonstrated a separation of the
samples to groups according to two methodological factors: (A) Two
different kit’s batches (Affymetrix whole-transcript target labeling kit) that
were reflected by the scan date, and (B) Two different researchers that
extracted the RNAs. (C) and (D), the PCA mapping that was done after
the removal of these two methodological effects, respectively,
demonstrated homogeneity of data.
Additional file 2: Supplemental Table 1: Differentially expressed
genes. List of the 115 genes (and 206 probesets) whose expression
levels were significantly changed between PD-patients and controls.
Asterisks (*) denote alternatively-spliced genes.
Additional file 3: Supplemental Table 2: Enriched GO-annotations in
the 115 differentially expressed genes. Full list of the significantly
over-represented GO-annotations among the 115 significantly changed
genes. O, Observed number of genes carrying the annotation among the
115 differentially expressed genes; E, expected number of genes that
carry this annotation among all core-level genes on the array; R, ratio
between observed and expected; P, P-value of the enrichment,
calculated using Fisher exact test.
Additional file 4: Supplemental Table 3: List of B cell-related genes
on the Exon 1.0 array. Combined list of all B cell-related genes that are
represented on the core-level Exon 1.0 array, which were extracted
based on their annotations from multiple databases (DAVID functional
analysis tools: GO, KEGG, Biocarta, BBID, UniProt Tissue and UniProt
Keywords databases [23,24]).
Additional file 5: Supplemental Table 4: Summary of Pearson
correlation analysis. A list of all correlated genes detected among the
115 significantly changed transcripts within all 59 RNA samples (Pearson
Correlation test, threshold: r > 0.8 and P <1 0
-14).
Additional file 6: Supplemental Table 5: Validation of expression
analysis. Results of the validation analyses that tested the expression
levels of 10 genes in 9 PD-patient and 6 control samples. Detailed are
the mean and SD obtained by both the Human Exon 1.0 ST array and
the quantitative real-time RT-PCR analyses, as well as the results and
significance of the Pearson Correlation test, which compared the
expression levels that resulted from these two methods.
Additional file 7: Supplemental Figure 2: B cell-related genes
expression in non-Ashekanazi PD patients. Quantitative Real-Time RT-
PCR analyses were performed to confirm the expression changes in
IGHD, IGHM, CD19 and CD22 in 10 non-Ashkenazi female PD patients and
11 non-Ashkenazi female controls. Each transcript’s expression level was
normalized to the geometric mean of GUSB and TBP expression levels.
Bars represent mean ± SD.
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